SAN DIEGO, CA / ACCESSWIRE / August 10, 2023 / Modular Medical, Inc. (the "Company" or "Modular Medical") (Nasdaq:MODD), a development stage insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced that Jeb Besser, CEO, is scheduled to present at the Sidoti Micro-Cap Virtual Conference on August 17. Mr. Besser will also host meetings with participating investors throughout the day during this virtual event.
The presentation will begin at 12:15 p.m. ET on Thursday, August 17, and can be accessed live here. Registration is free and investors are not required to be a Sidoti client. To schedule a one-on-one meeting, please visit www.sidoti.com/events.
About Modular Medical
Modular Medical, Inc. (Nasdaq:MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Our mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."
Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding MODD, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.
All trademarks mentioned herein are the property of their respective owners.
CONTACT:
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.42 |
| Daily Change: | 0.02 5.65 |
| Daily Volume: | 68,480 |
| Market Cap: | US$26.390M |
November 14, 2025 November 03, 2025 October 28, 2025 September 29, 2025 | |

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load